Losartan Use in Advanced Chronic Kidney Disease (eGFR <30 mL/min/1.73 m²)
Losartan can and should be continued in patients with chronic kidney disease even when eGFR falls below 30 mL/min/1.73 m², particularly if there is proteinuria, and no dose adjustment is required based on renal function alone. 1
Key Recommendations for Advanced CKD
Continue ARBs/ACE Inhibitors Below eGFR 30
The 2024 KDIGO guidelines explicitly state: "Continue ACEi or ARB in people with CKD even when the eGFR falls below 30 ml/min per 1.73 m²" 1. This represents the most current, authoritative guidance and directly addresses your question.
Dosing Guidelines
- Standard dosing applies: Losartan 50-100 mg once or twice daily 2, 3, 4
- No renal dose adjustment needed: Unlike many other medications, losartan does not require dose reduction based solely on eGFR 5, 6
- Use maximum tolerated dose: The proven renoprotective benefits were achieved using the highest approved doses (typically 100 mg daily) 1
When to Use Losartan in Advanced CKD
Primary indications:
- Proteinuria (albumin-to-creatinine ratio ≥30 mg/mmol or ≥300 mg/g) 1
- Hypertension requiring treatment 7, 8
- Diabetic nephropathy with elevated creatinine and proteinuria 9
The 2024 KDIGO guidelines recommend starting RAS inhibitors for patients with moderately-to-severely increased albuminuria (A2-A3) across all CKD stages G1-G4 1. Notably, this recommendation extends through stage 4 CKD (eGFR 15-29 mL/min/1.73 m²).
Critical Monitoring Requirements
Initial and Ongoing Monitoring
Check within 2-4 weeks of initiation or dose increase 1, 7:
- Serum creatinine
- Serum potassium
- Blood pressure
When to Continue Despite Changes
Continue losartan unless 1, 7:
- Serum creatinine rises >30% within 4 weeks of initiation/dose increase
- Symptomatic hypotension occurs
- Uncontrolled hyperkalemia persists despite medical management
- Uremic symptoms develop while treating kidney failure (eGFR <15 mL/min/1.73 m²)
Hyperkalemia Management
Do not automatically discontinue for hyperkalemia 1, 7. The guidelines emphasize that hyperkalemia can often be managed through:
- Dietary potassium restriction
- Potassium binders
- Diuretic adjustment
- Treatment of metabolic acidosis
Only reduce dose or discontinue if hyperkalemia remains uncontrolled despite these measures.
Special Considerations for eGFR <30
Loop Diuretics Preferred Over Thiazides
When eGFR <30 mL/min, loop diuretics (furosemide, torsemide, bumetanide) are preferred over thiazide diuretics 2, 3, 4. However, the thiazide-like diuretic chlorthalidone remains effective even in stage 4 CKD 10.
Combination Therapy Restrictions
Never combine losartan with ACE inhibitors or direct renin inhibitors 2, 1. This combination increases risks of hyperkalemia, hypotension, and acute kidney injury without additional benefit.
Pharmacokinetic Data Supporting Use
Research demonstrates that losartan pharmacokinetics are minimally altered in end-stage renal disease, including hemodialysis patients 6. The drug and its active metabolite (E-3174) are not dialyzable, so no post-dialysis supplementation is needed 6.
Clinical Evidence in Advanced CKD
A study specifically evaluating losartan in patients with moderate-to-severe renal insufficiency (eGFR 10-29 mL/min) and hemodialysis patients showed:
- Effective blood pressure reduction (-14.1/-10.6 mmHg in moderate-severe CKD)
- Stable creatinine clearance and glomerular filtration rate
- Well-tolerated with minimal hyperkalemia (only 1 patient required discontinuation) 5
Common Pitfalls to Avoid
- Don't automatically reduce dose based on eGFR alone - This is unnecessary and may reduce renoprotective benefit
- Don't stop for mild creatinine increases - Up to 30% increase within 4 weeks is acceptable and often represents hemodynamic changes rather than kidney injury
- Don't discontinue prematurely for hyperkalemia - Implement potassium-lowering strategies first
- Don't combine with other RAS inhibitors - This increases harm without benefit
- Don't forget volume status - Correct volume depletion before initiating to avoid hypotension 9
When to Consider Discontinuation
Consider reducing dose or stopping 1:
- eGFR <15 mL/min/1.73 m² with uremic symptoms
- Persistent symptomatic hypotension
- Refractory hyperkalemia despite maximal medical management
- Acute kidney injury with creatinine rise >30% within 4 weeks
- Bilateral renal artery stenosis or solitary kidney with stenosis 11, 12
The evidence strongly supports continuing losartan in advanced CKD for its renoprotective effects, particularly in proteinuric patients, with careful monitoring but without automatic dose reduction based on eGFR alone.